Continuity Biosciences, LLC filed a Form D with the Securities and Exchange Commission on 2025-08-19.
Continuity Biosciences, LLC filed a Form D notice of an exempt securities offering with the SEC on August 19, 2025. The filing reports $8.42M sold. Its industry group is Biotechnology. It names Ramakrishna Venugopalan (Executive Officer, Director), Robert Whitehead (Director), Michael Fowler (Director) (SEC Form D, August 19, 2025).
Is this your company?
Sell to companies like Continuity Biosciences, LLC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Continuity Biosciences, LLC.
Free to see. No signup.
More on the people and the money behind Continuity Biosciences, LLC, from the filings we hold.
Biotechnology raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when Continuity Biosciences, LLC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Continuity Biosciences, LLC raises, hires or launches. No email unless you switch it on.
Watch Continuity Biosciences, LLC →Get the full cited report on Continuity Biosciences, LLC
What the filing shows about Continuity Biosciences, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Continuity Biosciences, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Continuity Biosciences, LLC's address as 8476 Lindrick Lane, Bradenton, FL 34202.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Continuity Biosciences, LLC See pricing
Continuity Biosciences, LLC is a registered filer with the SEC (CIK 2029079) and has filed since 2024-07-02. 3 filings are on record, the latest on 2025-08-19.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Continuity Biosciences, LLC's Form D of 2025-08-19 names Ramakrishna Venugopalan, Robert Whitehead, Michael Fowler and 4 more as its officers, directors or promoters.
Its new offerings report $11.87M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Ramakrishna Venugopalan is named as Executive Officer and Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Robert Whitehead is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Michael Fowler is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Monica Reed is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Allen Weiss is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Josephine Torrente is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
Joseph DeSimone is named as Director on the Form D that Continuity Biosciences, LLC filed with the SEC on 19 August 2025, one of 7 people that filing names.
7 people named on the filing — 1 holding an executive role and 6 as directors only.
Named as of the 2025-08-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Continuity Biosciences, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Continuity Biosciences, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Continuity Biosciences, LLC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Continuity Biosciences, LLCYou get an alert in MentionFox the next time this company shows up.
If you're behind Continuity Biosciences, LLC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Continuity Biosciences, LLC. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/continuity-biosciences-llc-form-d-25000001